Robert J. Spiegel, M.D., FACP
Compensation Committee (Chair)
Robert J. Spiegel, M.D., FACP, has served as a director of Geron since May 2010.
Dr. Spiegel currently serves as an Associate Professor at the Weill Cornell Medical School, a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund. He is also a member of the board of directors of Ayala Pharmaceuticals since December 2017; Cyclacel Pharmaceuticals, Inc. since September 2018; Athenex, Inc. since August 2020; and several privately-held biotechnology companies. He previously served as a director for Avior Computing Corporation from October 2011 to November 2017; Talon Therapeutics, Inc. from July 2010 to July 2013; Capstone Therapeutics Corp. from May 2010 to January 2012; Sucampo Pharmaceuticals, Inc. from January 2015 to January 2018; and PDS Biotechnology Corporation (formerly Edge Therapeutics, Inc.) from August 2013 to March 2019; the Cancer Institute of New Jersey from 1999 to 2009; and Cancer Care New Jersey from 1995 to 2011. From March 2011 to April 2016, Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc.
In 2009, after 26 years with the Schering-Plough Corporation (now Merck & Co.), Dr. Spiegel retired as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. His career at Schering-Plough involved various positions, including Director of clinical research for oncology, Vice President of clinical research, and Senior Vice President of worldwide clinical research. Following a residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.